Literature DB >> 7869183

Chemiluminescent immunoassays: discrimination between the reactivities of natural and human patient antibodies with antigens from eukaryotic pathogens, Trypanosoma cruzi and Paracoccidioides brasiliensis.

I C Almeida1, E G Rodrigues, L R Travassos.   

Abstract

Quantitative chemiluminescent enzyme-linked immunosorbent assay (ELISA) and dot-blotting procedures were developed to evaluate the reactivity of human antibodies with crude antigens and purified molecules of parasites and fungi, mainly Trypanosoma cruzi and Paracoccidioides brasiliensis. Reproducible, highly sensitive, and strictly dose-responding results were obtained, with the specificity depending on the kind of antigen used. Mixed antigens (epimastigote membrane and HIV-1 heptapeptide) applied in dots could be independently recognized by specific sera. Purified antigens (T. cruzi F2/3 and P. brasiliensis gp43) at very small concentrations gave specific reactions with patients' sera diluted > or = 1:1,000 and were very poorly reactive or unreactive with natural antibodies using the chemiluminescent immunoassays. P. brasiliensis crude antigen Fava Netto polysaccharide antigen (FNPA) contained peptide epitopes recognized by natural antibodies and carbohydrate epitopes reactive with sera from histoplasmosis patients. It is very important that sensitive chemiluminescence immunoassays be used with purified antigenic molecules to ensure specificity for the diagnosis and follow-up of parasitic and fungal infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7869183     DOI: 10.1002/jcla.1860080614

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  8 in total

1.  Differential inhibitory mechanism of cyclic AMP on TNF-alpha and IL-12 synthesis by macrophages exposed to microbial stimuli.

Authors:  D O Procópio; M M Teixeira; M M Camargo; L R Travassos; M A Ferguson; I C Almeida; R T Gazzinelli
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Expression in bacteria of the gene encoding the gp43 antigen of paracoccidioides brasiliensis: immunological reactivity of the recombinant fusion proteins.

Authors:  Susana N Diniz; Kátia C Carvalho; Patrícia S Cisalpino; José F Silveira; Luiz R Travassos; Rosana Puccia
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

3.  HLA class I and II profiles of patients presenting with Chagas' disease.

Authors:  N H Deghaide; R O Dantas; E A Donadi
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

4.  TNF microsatellite alleles in Brazilian Chagasic patients.

Authors:  Viriato Campelo; Roberto O Dantas; Renata T Simões; Celso T Mendes-Junior; Sandra M B Sousa; Aguinaldo L Simões; Eduardo A Donadi
Journal:  Dig Dis Sci       Date:  2007-08-23       Impact factor: 3.199

5.  Use of recombinant gp43 isoforms expressed in Pichia pastoris for diagnosis of paracoccidioidomycosis.

Authors:  K C Carvalho; M C Vallejo; Z P Camargo; R Puccia
Journal:  Clin Vaccine Immunol       Date:  2008-01-30

6.  A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage.

Authors:  Javier M Di Noia; Carlos A Buscaglia; Claudia R De Marchi; Igor C Almeida; Alberto C C Frasch
Journal:  J Exp Med       Date:  2002-02-18       Impact factor: 14.307

Review 7.  Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin.

Authors:  Galia Ramírez-Toloza; Arturo Ferreira
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

8.  Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1.

Authors:  Maria Helena C Rodrigues; Maristela G Cunha; Ricardo LD Machado; Orlando C Ferreira; Mauricio M Rodrigues; Irene S Soares
Journal:  Malar J       Date:  2003-11-14       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.